Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML But it's unlikely stem cell transplants will ever be large-scale cure for HIV, says expert Feb 14, 2024
FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia Complete response rate of 86%, median event-free survival approaching 4 years with crenolanib Feb 13, 2024
No Relief From Drug Shortages; New Lymphedema Guideline; A 'Good' Patient No More News, features, and commentary about cancer-related issues Feb 09, 2024
All-Oral Therapy Promising in Higher-Risk MDS, CMML In small trial, overall response rate was 95% Feb 05, 2024
Camp Lejeune Water Contamination Tied to a Range of Cancers, CDC Study Says Health risks now more firmly established, but study falls short of being definitive Feb 01, 2024
When a Revolutionary Cancer Treatment Causes Cancer The potential benefits of CAR T-cell therapies still far outweigh the risks Jan 27, 2024
CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning Post-treatment cases grow to 22 since products' initial approvals Jan 24, 2024
FDA Calls for New Boxed Warning on All CAR-T Products Most serious warning would alert patients, providers on potential risk for secondary malignancies Jan 23, 2024
Two Million Cancers; Casgevy OK'd for Thalassemia; Rectal Exams and Prostate Cancer News, features, and commentary about cancer-related issues Jan 19, 2024
Carvedilol No Help in Preventing Heart Failure in Childhood Cancer Survivors While safe, the results do not support use of the drug in anthracycline-exposed survivors Jan 10, 2024
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear Dec 10, 2023
Completely Oral Regimen Effective, Feasible in APL 97% of patients alive and relapse-free at 3 years Dec 10, 2023
Non-Covalent BTK Inhibitor Approved for CLL Response rates with pirtobrutinib reached 72% in heavily pretreated patient population Dec 04, 2023
Charting the Course: From Young Adult Leukemia Patient to Oncologist My experience shaped how I care for patients today Dec 03, 2023
FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy Applies to all approved therapies, but benefits still outweigh risks, agency says Nov 28, 2023
Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL However, it may benefit children at increased risk of thrombosis Nov 20, 2023
Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia News, features, and commentary about cancer-related issues Nov 03, 2023
Soap to Fight Skin Cancer; $1,000 Early Cancer Detection Test; FDA Approval in MDS News, features, and commentary about cancer-related issues Oct 27, 2023
Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment News, features, and commentary about cancer-related issues Oct 19, 2023
Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines; Struggling to Live News, features, and commentary about cancer-related issues Oct 06, 2023
Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening News, features, and commentary about cancer-related issues Sep 28, 2023
Frontline Combo Yields High Remission Rate in Hairy Cell Leukemia And almost all complete responders in small trial achieved MRD negativity Sep 25, 2023
FLT3 Inhibitor Improves AML Survival With or Without Stem-Cell Transplant Best outcomes with transplantation, but non-transplant patients also benefited from quizartinib Sep 11, 2023
Early Major Response to Ponatinib in Pretreated CML Portends Better Outcomes Molecular or cytogenetic response at 3 months correlated with better survival Sep 08, 2023
Intensive Pretransplant Consolidation in Older AML Fails to Improve Results Newer therapies and strategies might show more promise for boosting survival Sep 07, 2023
Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care News, features, and commentary about cancer-related issues Sep 07, 2023
More Intense ALL Therapy Improves Outcomes in Adolescents, Young Adults Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival Sep 07, 2023
Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL 73% of patients with prior exposure to covalent BTK inhibitors responded Jul 05, 2023
WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer News, features, and commentary about cancer-related issues Jun 29, 2023
No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL Study suggests "watch and wait" should remain standard of care Jun 28, 2023
Earlier Detection of Cardiac Dysfunction Possible for Young Adult Cancer Survivors A case for monitoring global longitudinal strain despite normal LVEF Jun 20, 2023
Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
Base-Edited CAR-T Product 'Potent' in Relapsed Childhood T-Cell ALL One young patient achieved molecular remission within 28 days of infusion Jun 14, 2023
CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients 5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital May 25, 2023
Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML But trial detects "meaningful benefit" when it comes to relapse, editorialists say May 15, 2023
FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia Median OS improved from 15 months to nearly 32 months with quizartinib May 09, 2023
Blinatumomab Plus Chemo Effective in Aggressive Infant ALL Low incidence of relapse after treatment "remarkable," researchers say Apr 26, 2023
